Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Post by fossi_2002on May 08, 2023 11:24am
105 Views
Post# 35436437

Price action

Price actionI don't think we'll see any increase in 1Q over the very strong 1Q 2022. My estimate is between 5-5.5 mill sales. However, I am sure we will see an increase in revenue during 2023. However, I do not see another sharp drop in share price towards mid40s. I rather think the stock market is already anticipating the worse Q1 numbers.
If I had more confidence in Gilles' abilities, I would say we are close to buy prices. But if the stock market already has no confidence in Gilles, why should shareholders have confidence in him? The AGM will show that the voices against Gilles have continued to grow. So far, I have not noticed anything of his announced "shareholderValue thoughts".


<< Previous
Bullboard Posts
Next >>